M Lipsitch

List of Publications by Year in Descending Order

446 papers	32,032 citations	93 h-index	166 g-index
502 ext. papers	40,475 ext. citations	11.5 avg, IF	8.19 L-index

#	Paper	IF	Citations
446	Indirect protection of children from SARS-CoV-2 infection through parental vaccination.. *Science*, **2022**, 375, eabm3087	33.3	8
445	Identifying and alleviating bias due to differential depletion of susceptible people in post-marketing evaluations of COVID-19 vaccines.. *American Journal of Epidemiology*, **2022**,	3.8	8
444	Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study.. *BMJ, The*, **2022**, 376, e068414	5.9	6
443	Antibiotic prescribing across age groups in the Kaiser Permanente Northern California population in association with different diagnoses, and with influenza incidence, 2010-2018.. *Epidemiology and Infection*, **2022**, 150, e85	4.3	
442	Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data.. *PLoS Computational Biology*, **2022**, 18, e1009964	5	1
441	Analysis of multiple bacterial species and antibiotic classes reveals large variation in the association between seasonal antibiotic use and resistance.. *PLoS Biology*, **2022**, 20, e3001579	9.7	0
440	Deep-sequence phylogenetics to quantify patterns of HIV transmission in the context of a universal testing and treatment trial - BCPP/ Ya Tsie trial.. *ELife*, **2022**, 11,	8.9	1
439	Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.. *New England Journal of Medicine*, **2022**,	59.2	24
438	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. *Nature Reviews Immunology*, **2021**,	36.5	36
437	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape.. *Cell*, **2021**, 184, 6229-6242.e18	56.2	19
436	Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study. *EClinicalMedicine*, **2021**, 42, 101190	11.3	4
435	Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents. *New England Journal of Medicine*, **2021**, 385, 2101-2103	59.2	30
434	Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. *Lancet, The*, **2021**, 398, 2093-2100	40	198
433	Model-informed COVID-19 vaccine prioritization strategies by age and serostatus **2021**,		47
432	Estimating epidemiologic dynamics from cross-sectional viral load distributions **2021**,		34
431	Burden of Antimicrobial Resistance: Compared to What?. *Epidemiologic Reviews*, **2021**,	4.1	4
430	Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure. *Clinical Microbiology and Infection*, **2021**, 27, 372-377	9.5	3

429	BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *New England Journal of Medicine*, **2021**, 384, 1412-1423	59.2	1137
428	Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. *Nature Reviews Immunology*, **2021**, 21, 330-335	36.5	46
427	Modeling the impact of racial and ethnic disparities on COVID-19 epidemic dynamics. *ELife*, **2021**, 10,	8.9	6
426	Leveraging Pathogen Sequence and Contact Tracing Data to Enhance Vaccine Trials in Emerging Epidemics. *Epidemiology*, **2021**, 32, 698-704	3.1	0
425	Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. *BMJ, The*, **2021**, 373, n1098	5.9	67
424	Estimating the cumulative incidence of COVID-19 in the United States using influenza surveillance, virologic testing, and mortality data: Four complementary approaches. *PLoS Computational Biology*, **2021**, 17, e1008994	5	7
423	Interpreting vaccine efficacy trial results for infection and transmission. *Vaccine*, **2021**, 39, 4082-4088	4.1	24
422	Estimating epidemiologic dynamics from cross-sectional viral load distributions. *Science*, **2021**, 373,	33.3	61
421	Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. *Vaccine*, **2021**, 39, 4013-4024	4.1	31
420	On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community. *Journal of Infectious Diseases*, **2021**, 223, 362-369	7	123
419	Potential Biases Arising From Epidemic Dynamics in Observational Seroprotection Studies. *American Journal of Epidemiology*, **2021**, 190, 328-335	3.8	5
418	Nowcasting for Real-Time COVID-19 Tracking in New York City: An Evaluation Using Reportable Disease Data From Early in the Pandemic. *JMIR Public Health and Surveillance*, **2021**, 7, e25538	11.4	8
417	Negative frequency-dependent selection and asymmetrical transformation stabilise multi-strain bacterial population structures. *ISME Journal*, **2021**, 15, 1523-1538	11.9	4
416	Estimating internationally imported cases during the early COVID-19 pandemic. *Nature Communications*, **2021**, 12, 311	17.4	15
415	Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data **2021**,		2
414	The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials. *JAMA - Journal of the American Medical Association*, **2021**, 325, 219-220	27.4	23
413	How to test SARS-CoV-2 vaccines ethically even after one is available. *Clinical Infectious Diseases*, **2021**,	11.6	4
412	Interpreting vaccine efficacy trial results for infection and transmission **2021**,		16

411	Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. *Science*, **2021**, 371, 916-921	33.3	284
410	How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19. *European Journal of Epidemiology*, **2021**, 36, 179-196	12.1	35
409	Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. *New England Journal of Medicine*, **2021**, 385, 1474-1484	59.2	459
408	Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. *Lancet Regional Health - Europe, The*, **2021**, 7, 100150		50
407	Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load. *Epidemiology*, **2021**, 32, 820-828	3.1	3
406	Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. *Lancet Infectious Diseases, The*, **2021**,	25.5	22
405	Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh. *Vaccine*, **2021**, 39, 5600-5606	4.1	4
404	Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *New England Journal of Medicine*, **2021**, 385, 1078-1090	59.2	225
403	Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. *Nature Medicine*, **2021**, 27, 1693-1695	36.9	50
402	Determinants of Staphylococcus aureus carriage in the developing infant nasal microbiome. *Genome Biology*, **2020**, 21, 301	18.3	4
401	Lockdown measures and relative changes in the age-specific incidence of SARS-CoV-2 in Spain. *Epidemiology and Infection*, **2020**, 148, e268	4.3	1
400	The role of "spillover" in antibiotic resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 29063-29068	11.5	9
399	Estimated Demand for US Hospital Inpatient and Intensive Care Unit Beds for Patients With COVID-19 Based on Comparisons With Wuhan and Guangzhou, China. *JAMA Network Open*, **2020**, 3, e208297	10.4	63
398	Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study. *BMC Medicine*, **2020**, 18, 129	11.4	9
397	Response to Dawson et al. *Journal of Infectious Diseases*, **2020**, 222, 516-517	7	1
396	Estimating case fatality rates of COVID-19. *Lancet Infectious Diseases, The*, **2020**, 20, 775	25.5	30
395	Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. *Nature Medicine*, **2020**, 26, 506-510	50.5	766
394	Aggregated mobility data could help fight COVID-19. *Science*, **2020**, 368, 145-146	33.3	183

393	Identifying Locations with Possible Undetected Imported Severe Acute Respiratory Syndrome Coronavirus 2 Cases by Using Importation Predictions. *Emerging Infectious Diseases*, **2020**, 26, 1465-1469	10.2	27
392	The relation between prescribing of different antibiotics and rates of mortality with sepsis in US adults. *BMC Infectious Diseases*, **2020**, 20, 169	4	3
391	Defining the Epidemiology of Covid-19 - Studies Needed. *New England Journal of Medicine*, **2020**, 382, 1194-1196	59.2	702
390	Response to Cioffi. *Journal of Infectious Diseases*, **2020**, 222, 169-170	7	6
389	Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. *Journal of Infectious Diseases*, **2020**, 221, 1752-1756	7	138
388	Using Genetic Distance from Archived Samples for the Prediction of Antibiotic Resistance in. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	2
387	Antibody testing will enhance the power and accuracy of COVID-19-prevention trials. *Nature Medicine*, **2020**, 26, 818-819	50.5	35
386	Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science*, **2020**, 368, 860-868	33.3	1506
385	Using observational data to quantify bias of traveller-derived COVID-19 prevalence estimates in Wuhan, China. *Lancet Infectious Diseases, The*, **2020**, 20, 803-808	25.5	42
384	Horizontal gene transfer rate is not the primary determinant of observed antibiotic resistance frequencies in. *Science Advances*, **2020**, 6, eaaz6137	14.3	10
383	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae. *PLoS Biology*, **2020**, 18, e3000878	9.7	5
382	Practical considerations for measuring the effective reproductive number, Rt. *PLoS Computational Biology*, **2020**, 16, e1008409	5	140
381	Estimating internationally imported cases during the early COVID-19 pandemic **2020**,		3
380	Temporal rise in the proportion of younger adults and older adolescents among coronavirus disease (COVID-19) cases following the introduction of physical distancing measures, Germany, March to April 2020. *Eurosurveillance*, **2020**, 25,	19.8	28
379	Potential impact of outpatient stewardship interventions on antibiotic exposures of common bacterial pathogens. *ELife*, **2020**, 9,	8.9	4
378	Targeted surveillance strategies for efficient detection of novel antibiotic resistance variants. *ELife*, **2020**, 9,	8.9	2
377	Using predicted imports of 2019-nCoV cases to determine locations that may not be identifying all imported cases **2020**,		34
376	Quantifying bias of COVID-19 prevalence and severity estimates in Wuhan, China that depend on reported cases in international travelers **2020**,		46

375	Comparative Impact of Individual Quarantine vs. Active Monitoring of Contacts for the Mitigation of COVID-19: a modelling study **2020**,		24
374	The demand for inpatient and ICU beds for COVID-19 in the US: lessons from Chinese cities **2020**,		31
373	Temporal rise in the proportion of both younger adults and older adolescents among COVID-19 cases in Germany: evidence of lesser adherence to social distancing practices? **2020**,		5
372	Estimating the Cumulative Incidence of COVID-19 in the United States Using Four Complementary Approaches **2020**,		26
371	Statistical Properties of Stepped Wedge Cluster-Randomized Trials in Infectious Disease Outbreaks **2020**,		2
370	Potential biases arising from epidemic dynamics in observational seroprotection studies **2020**,		2
369	Practical considerations for measuring the effective reproductive number, **2020**,		46
368	Lockdown measures and relative changes in the age-specific incidence of SARS-CoV-2 in Spain **2020** ,		5
367	On the effect of age on the transmission of SARS-CoV-2 in households, schools and the community **2020**,		35
366	Novel methods for the analysis of stepped wedge cluster randomized trials. *Statistics in Medicine*, **2020**, 39, 815-844	2.3	11
365	The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology. *Epidemiology*, **2020**, 31, 43-64	3.1	32
364	Understanding COVID-19 vaccine efficacy. *Science*, **2020**, 370, 763-765	33.3	98
363	Cross-reactive memory T cells and herd immunity to SARS-CoV-2. *Nature Reviews Immunology*, **2020** , 20, 709-713	36.5	132
362	Reply to Hasford and to Spinola et al. *Journal of Infectious Diseases*, **2020**, 222, 1574-1575	7	
361	Statistical Properties of Stepped Wedge Cluster-Randomized Trials in Infectious Disease Outbreaks. *American Journal of Epidemiology*, **2020**, 189, 1324-1332	3.8	3
360	Testing COVID-19 therapies to prevent progression of mild disease. *Lancet Infectious Diseases, The*, **2020**, 20, 1367	25.5	9
359	Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution. *New England Journal of Medicine*, **2020**, 383, 1941-1950	59.2	32
358	Opinion: It's ethical to test promising coronavirus vaccines against less-promising ones. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 18898-18901	11.5	

357	Reopening Primary Schools during the Pandemic. *New England Journal of Medicine*, **2020**, 383, 981-985	59.2	99
356	Good science is good science: we need specialists, not sects. *European Journal of Epidemiology*, **2020**, 35, 519-522	12.1	0
355	Depletion-of-susceptibles Bias in Analyses of Intra-season Waning of Influenza Vaccine Effectiveness. *Clinical Infectious Diseases*, **2020**, 70, 1484-1486	11.6	15
354	Nowcasting by Bayesian Smoothing: A flexible, generalizable model for real-time epidemic tracking. *PLoS Computational Biology*, **2020**, 16, e1007735	5	43
353	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae **2020**, 18, e3000878		
352	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae **2020**, 18, e3000878		
351	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae **2020**, 18, e3000878		
350	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae **2020**, 18, e3000878		
349	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae **2020**, 18, e3000878		
348	Frequency-dependent selection can forecast evolution in Streptococcus pneumoniae **2020**, 18, e3000878		
347	Influenza A Hemagglutinin Passage Bias Sites and Host Specificity Mutations. *Cells*, **2019**, 8,	7.9	2
346	Levels of outpatient prescribing for four major antibiotic classes and rates of septicemia hospitalization in adults in different US states - a statistical analysis. *BMC Public Health*, **2019**, 19, 1138	4.1	2
345	Modelling the epidemiologic impact of achieving UNAIDS fast-track 90-90-90 and 95-95-95 targets in South Africa. *Epidemiology and Infection*, **2019**, 147, e122	4.3	8
344	On the role of different age groups during pertussis epidemics in California, 2010 and 2014. *Epidemiology and Infection*, **2019**, 147, e184	4.3	1
343	On the evolutionary ecology of multidrug resistance in bacteria. *PLoS Pathogens*, **2019**, 15, e1007763	7.6	30
342	Resistance diagnostics as a public health tool to combat antibiotic resistance: A model-based evaluation. *PLoS Biology*, **2019**, 17, e3000250	9.7	20
341	Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states. *International Journal of Antimicrobial Agents*, **2019**, 54, 23-34	14.3	16
340	Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose. *Scientific Reports*, **2019**, 9, 3203	4.9	10

339	Herd immunity alters the conditions for performing dose schedule comparisons: an individual-based model of pneumococcal carriage. *BMC Infectious Diseases*, **2019**, 19, 227	4	5
338	THE AUTHORS REPLY. *American Journal of Epidemiology*, **2019**, 188, 807-808	3.8	1
337	Regulating impact on bystanders in clinical trials: An unsettled frontier. *Clinical Trials*, **2019**, 16, 450-454	2.2	4
336	Comment on: 'Antibiotic footprint' as a communication tool to aid reduction of antibiotic consumption. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 3404-3406	5.1	1
335	Enhancing Situational Awareness to Prevent Infectious Disease Outbreaks from Becoming Catastrophic. *Current Topics in Microbiology and Immunology*, **2019**, 424, 59-74	3.3	12
334	Postexposure Effects of Vaccines on Infectious Diseases. *Epidemiologic Reviews*, **2019**, 41, 13-27	4.1	15
333	Surveillance to maintain the sensitivity of genotype-based antibiotic resistance diagnostics. *PLoS Biology*, **2019**, 17, e3000547	9.7	8
332	Interaction Patterns of Men Who Have Sex With Men on a Geosocial Networking Mobile App in Seven United States Metropolitan Areas: Observational Study. *Journal of Medical Internet Research*, **2019**, 21, e13766	7.6	2
331	Response to comment on 'The distribution of antibiotic use and its association with antibiotic resistance'. *ELife*, **2019**, 8,	8.9	1
330	Population genomics of pneumococcal carriage in Massachusetts children following introduction of PCV-13. *Microbial Genomics*, **2019**, 5,	4.4	7
329	Case-based surveillance of antimicrobial resistance with full susceptibility profiles. *JAC-Antimicrobial Resistance*, **2019**, 1, dlz070	2.9	10
328	Mathematical modelling for antibiotic resistance control policy: do we know enough?. *BMC Infectious Diseases*, **2019**, 19, 1011	4	21
327	Hospitalizations Associated with Respiratory Syncytial Virus and Influenza in Children, Including Children Diagnosed with Asthma. *Epidemiology*, **2019**, 30, 918-926	3.1	9
326	Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results. *Epidemiology and Infection*, **2019**, 147, e306	4.3	12
325	Azithromycin Susceptibility Among Neisseria gonorrhoeae Isolates and Seasonal Macrolide Use. *Journal of Infectious Diseases*, **2019**, 219, 619-623	7	26
324	Models of immune selection for multi-locus antigenic diversity of pathogens. *Nature Reviews Immunology*, **2019**, 19, 55-62	36.5	17
323	The Relative Impact of Community and Hospital Antibiotic Use on the Selection of Extended-spectrum Beta-lactamase-producing Escherichia coli. *Clinical Infectious Diseases*, **2019**, 69, 182-188	11.6	15
322	Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection. *American Journal of Epidemiology*, **2019**, 188, 467-474	3.8	16

321	Surveillance to maintain the sensitivity of genotype-based antibiotic resistance diagnostics **2019**, 17, e3000547		
320	Surveillance to maintain the sensitivity of genotype-based antibiotic resistance diagnostics **2019**, 17, e3000547		
319	Surveillance to maintain the sensitivity of genotype-based antibiotic resistance diagnostics **2019**, 17, e3000547		
318	Surveillance to maintain the sensitivity of genotype-based antibiotic resistance diagnostics **2019**, 17, e3000547		
317	Surveillance to maintain the sensitivity of genotype-based antibiotic resistance diagnostics **2019**, 17, e3000547		
316	Surveillance to maintain the sensitivity of genotype-based antibiotic resistance diagnostics **2019**, 17, e3000547		
315	Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials. *American Journal of Epidemiology*, **2018**, 187, 1763-1771	3.8	14
314	Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data. *Vaccine*, **2018**, 36, 473-478	4.1	6
313	Weak Epistasis May Drive Adaptation in Recombining Bacteria. *Genetics*, **2018**, 208, 1247-1260	4	30
312	On the Relative Role of Different Age Groups During Epidemics Associated With Respiratory Syncytial Virus. *Journal of Infectious Diseases*, **2018**, 217, 238-244	7	19
311	The evolution of antibiotic resistance in a structured host population. *Journal of the Royal Society Interface*, **2018**, 15,	4.1	25
310	Can antibiotic resistance be reduced by vaccinating against respiratory disease?. *Lancet Respiratory Medicine,the*, **2018**, 6, 820-821	35.1	9
309	Trends in outpatient antibiotic use and prescribing practice among US older adults, 2011-15: observational study. *BMJ, The*, **2018**, 362, k3155	5.9	38
308	Measurement of Vaccine Direct Effects Under the Test-Negative Design. *American Journal of Epidemiology*, **2018**, 187, 2686-2697	3.8	60
307	Why Do Exceptionally Dangerous Gain-of-Function Experiments in Influenza?. *Methods in Molecular Biology*, **2018**, 1836, 589-608	1.4	9
306	Choices in vaccine trial design in epidemics of emerging infections. *PLoS Medicine*, **2018**, 15, e1002632	11.6	22
305	Impact of Antimicrobial Treatment for Acute Otitis Media on Carriage Dynamics of Penicillin-Susceptible and Penicillin-Nonsusceptible Streptococcus pneumoniae. *Journal of Infectious Diseases*, **2018**, 218, 1356-1366	7	9
304	Antigenic Variation in PspC Promotes Immune Escape in the Presence of Variant-Specific Immunity. *MBio*, **2018**, 9,	7.8	16

303	Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination. *ELife*, **2018**, 7,	8.9	19
302	The distribution of antibiotic use and its association with antibiotic resistance. *ELife*, **2018**, 7,	8.9	69
301	Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E11988-E11995	11.5	76
300	Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 12911-12919	11.5	81
299	Microbiome as a tool and a target in the effort to address antimicrobial resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 12902-12910	11.5	42
298	Use of an individual-based model of pneumococcal carriage for planning a randomized trial of a whole-cell vaccine. *PLoS Computational Biology*, **2018**, 14, e1006333	5	6
297	Multidrug-resistant Neisseria gonorrhoeae: implications for future treatment strategies. *Lancet Infectious Diseases, The*, **2018**, 18, 599	25.5	6
296	Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials. *Clinical Trials*, **2018**, 15, 207-211	2.2	9
295	The impact of serotype-specific vaccination on phylodynamic parameters of Streptococcus pneumoniae and the pneumococcal pan-genome. *PLoS Pathogens*, **2018**, 14, e1006966	7.6	18
294	Preprints: An underutilized mechanism to accelerate outbreak science. *PLoS Medicine*, **2018**, 15, e1002549	11.6	60
293	Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration of carriage. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 1075-1080	11.5	81
292	Displacement of sexual partnerships in trials of sexual behavior interventions: A model-based assessment of consequences. *Epidemics*, **2017**, 20, 94-101	5.1	1
291	Vaccine testing for emerging infections: the case for individual randomisation. *Journal of Medical Ethics*, **2017**, 43, 625-631	2.5	8
290	Temporally Varying Relative Risks for Infectious Diseases: Implications for Infectious Disease Control. *Epidemiology*, **2017**, 28, 136-144	3.1	28
289	Population effect of influenza vaccination under co-circulation of non-vaccine variants and the case for a bivalent A/H3N2 vaccine component. *Epidemics*, **2017**, 19, 74-82	5.1	3
288	Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study. *Lancet Infectious Diseases, The*, **2017**, 17, 339-347	25.5	17
287	Diverse evolutionary patterns of pneumococcal antigens identified by pangenome-wide immunological screening. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E357-E366	11.5	42
286	Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period. *Pediatrics*, **2017**, 140,	7.4	24

285	Frequency-dependent selection in vaccine-associated pneumococcal population dynamics. *Nature Ecology and Evolution*, **2017**, 1, 1950-1960	12.3	69
284	Using simulation to aid trial design: Ring-vaccination trials. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005470	4.8	15
283	Simulations for designing and interpreting intervention trials in infectious diseases. *BMC Medicine*, **2017**, 15, 223	11.4	41
282	If a Global Catastrophic Biological Risk Materializes, at What Stage Will We Recognize It?. *Health Security*, **2017**, 15, 331-334	2.1	17
281	Antibiotic Consumption and Antibiotic Resistance Across Organisms, Drugs, and Consumer Groups. *Open Forum Infectious Diseases*, **2017**, 4, S18-S19	1	1
280	Host population structure and treatment frequency maintain balancing selection on drug resistance. *Journal of the Royal Society Interface*, **2017**, 14,	4.1	18
279	Improving vaccine trials in infectious disease emergencies. *Science*, **2017**, 357, 153-156	33.3	16
278	Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination. *Journal of the Royal Society Interface*, **2017**, 14,	4.1	12
277	Vaccine Effects on Heterogeneity in Susceptibility and Implications for Population Health Management. *MBio*, **2017**, 8,	7.8	24
276	Underprotection of Unpredictable Statistical Lives Compared to Predictable Ones. *Risk Analysis*, **2017**, 37, 893-904	3.9	5
275	Shared Genomic Variants: Identification of Transmission Routes Using Pathogen Deep-Sequence Data. *American Journal of Epidemiology*, **2017**, 186, 1209-1216	3.8	59
274	Pan-serotype Reduction in Progression of Streptococcus pneumoniae to Otitis Media After Rollout of Pneumococcal Conjugate Vaccines. *Clinical Infectious Diseases*, **2017**, 65, 1853-1861	11.6	19
273	Systematic analysis of protein identity between Zika virus and other arthropod-borne viruses. *Bulletin of the World Health Organization*, **2017**, 95, 517-525I	8.2	36
272	Association of Pneumococcal Protein Antigen Serology With Age and Antigenic Profile of Colonizing Isolates. *Journal of Infectious Diseases*, **2017**, 215, 713-722	7	17
271	Comment on "Gain-of-Function Research and the Relevance to Clinical Practice". *Journal of Infectious Diseases*, **2016**, 214, 1284-5	7	3
270	Genomic Epidemiology of Gonococcal Resistance to Extended-Spectrum Cephalosporins, Macrolides, and Fluoroquinolones in the United States, 2000-2013. *Journal of Infectious Diseases*, **2016**, 214, 1579-1587	7	141
269	Fractional dosing of yellow fever vaccine to extend supply: a modelling study. *Lancet, The*, **2016**, 388, 2904-2911	40	59
268	How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?. *MBio*, **2016**, 7,	7.8	109

267	Identifying the effect of patient sharing on between-hospital genetic differentiation of methicillin-resistant Staphylococcus aureus. *Genome Medicine*, **2016**, 8, 18	14.4	17
266	Improving Control of Antibiotic-Resistant Gonorrhea by Integrating Research Agendas Across Disciplines: Key Questions Arising From Mathematical Modeling. *Journal of Infectious Diseases*, **2016**, 213, 883-90	7	26
265	Infective endocarditis and cancer in the elderly. *European Journal of Epidemiology*, **2016**, 31, 41-9	12.1	16
264	Viral factors in influenza pandemic risk assessment. *ELife*, **2016**, 5,	8.9	61
263	Impact of Host Heterogeneity on the Efficacy of Interventions to Reduce Staphylococcus aureus Carriage. *Infection Control and Hospital Epidemiology*, **2016**, 37, 197-204	2	3
262	Zika vaccine trials. *Science*, **2016**, 353, 1094-5	33.3	7
261	Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies. *International Journal of Epidemiology*, **2016**, 45, 2060-2074	7.8	57
260	Sequence tag-based analysis of microbial population dynamics. *Nature Methods*, **2015**, 12, 223-6, 3 p following 226	21.6	70
259	Stability of the pneumococcal population structure in Massachusetts as PCV13 was introduced. *BMC Infectious Diseases*, **2015**, 15, 68	4	24
258	Inference of seasonal and pandemic influenza transmission dynamics. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 2723-8	11.5	102
257	Selective and genetic constraints on pneumococcal serotype switching. *PLoS Genetics*, **2015**, 11, e1005095	8.5	47
256	Carriage burden, multiple colonization and antibiotic pressure promote emergence of resistant vaccine escape pneumococci. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2015**, 370, 20140342	5.8	27
255	Vaccine testing. Ebola and beyond. *Science*, **2015**, 348, 46-8	33.3	16
254	Effect of Serotype on Pneumococcal Competition in a Mouse Colonization Model. *MBio*, **2015**, 6, e00902-15	7.8	30
253	Antibiotics in agriculture and the risk to human health: how worried should we be?. *Evolutionary Applications*, **2015**, 8, 240-7	4.8	267
252	The ethics of biosafety considerations in gain-of-function research resulting in the creation of potential pandemic pathogens. *Journal of Medical Ethics*, **2015**, 41, 901-8	2.5	21
251	On the relative role of different age groups in influenza epidemics. *Epidemics*, **2015**, 13, 10-16	5.1	71
250	Gain-of-function experiments: time for a real debate. *Nature Reviews Microbiology*, **2015**, 13, 58-64	22.2	33

249	Population genomic datasets describing the post-vaccine evolutionary epidemiology of Streptococcus pneumoniae. *Scientific Data*, **2015**, 2, 150058	8.2	40
248	Examining the role of different age groups, and of vaccination during the 2012 Minnesota pertussis outbreak. *Scientific Reports*, **2015**, 5, 13182	4.9	14
247	How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2015**, 370, 20140306	5.8	13
246	Enhancing disease surveillance with novel data streams: challenges and opportunities. *EPJ Data Science*, **2015**, 4,	3.4	96
245	Estimating the hospitalization burden associated with influenza and respiratory syncytial virus in New York City, 2003-2011. *Influenza and Other Respiratory Viruses*, **2015**, 9, 225-33	5.6	31
244	Identification of pneumococcal colonization determinants in the stringent response pathway facilitated by genomic diversity. *BMC Genomics*, **2015**, 16, 369	4.5	9
243	Reply to "Studies on influenza virus transmission between ferrets: the public health risks revisited". *MBio*, **2015**, 6,	7.8	11
242	Origin and proliferation of multiple-drug resistance in bacterial pathogens. *Microbiology and Molecular Biology Reviews*, **2015**, 79, 101-16	13.2	134
241	Potential Biases in Estimating Absolute and Relative Case-Fatality Risks during Outbreaks. *PLoS Neglected Tropical Diseases*, **2015**, 9, e0003846	4.8	124
240	Age- and sex-related risk factors for influenza-associated mortality in the United States between 1997-2007. *American Journal of Epidemiology*, **2014**, 179, 156-67	3.8	87
239	Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. *Lancet Infectious Diseases, The*, **2014**, 14, 220-6	25.5	162
238	Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure. *Journal of Virology*, **2014**, 88, 7286-93	6.6	38
237	In Vitro selection of Neisseria gonorrhoeae mutants with elevated MIC values and increased resistance to cephalosporins. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6986-9	5.9	13
236	Nuanced risk assessment for emerging infectious diseases. *Lancet, The*, **2014**, 383, 189-90	40	20
235	Estimating the per-exposure effect of infectious disease interventions. *Epidemiology*, **2014**, 25, 134-8	3.1	15
234	Can limited scientific value of potential pandemic pathogen experiments justify the risks?. *MBio*, **2014**, 5, e02008-14	7.8	9
233	Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa. *PLoS ONE*, **2014**, 9, e98272	3.7	15
232	Improving pandemic influenza risk assessment. *ELife*, **2014**, 3, e03883	8.9	45

231	Changing the Ecology of Pneumococci with Antibiotics and Vaccines **2014**, 281-313		1
230	Ethical alternatives to experiments with novel potential pandemic pathogens. *PLoS Medicine*, **2014**, 11, e1001646	11.6	84
229	Within-host bacterial diversity hinders accurate reconstruction of transmission networks from genomic distance data. *PLoS Computational Biology*, **2014**, 10, e1003549	5	108
228	A missing dimension in measures of vaccination impacts. *PLoS Pathogens*, **2014**, 10, e1003849	7.6	34
227	The distribution of pairwise genetic distances: a tool for investigating disease transmission. *Genetics*, **2014**, 198, 1395-404	4	31
226	A new approach to the analysis of antibiotic resistance data from hospitals. *Microbial Drug Resistance*, **2014**, 20, 583-90	2.9	3
225	Epidemiologic data and pathogen genome sequences: a powerful synergy for public health. *Genome Biology*, **2014**, 15, 538	18.3	66
224	Utilizing syndromic surveillance data for estimating levels of influenza circulation. *American Journal of Epidemiology*, **2014**, 179, 1394-401	3.8	20
223	The US 2009 A(H1N1) influenza epidemic: quantifying the impact of school openings on the reproductive number. *Epidemiology*, **2014**, 25, 203-6	3.1	20
222	A modified Janus cassette (Sweet Janus) to improve allelic replacement efficiency by high-stringency negative selection in Streptococcus pneumoniae. *PLoS ONE*, **2014**, 9, e100510	3.7	26
221	The association of meningococcal disease with influenza in the United States, 1989-2009. *PLoS ONE* , **2014**, 9, e107486	3.7	30
220	Author response: Improving pandemic influenza risk assessment **2014**,		2
219	Predictors of indoor absolute humidity and estimated effects on influenza virus survival in grade schools. *BMC Infectious Diseases*, **2013**, 13, 71	4	31
218	Avian influenza: Ferret H7N9 flu model questioned. *Nature*, **2013**, 501, 33	50.4	6
217	Applications of quantitative modeling to influenza virus transmission dynamics, antigenic and genetic evolution, and molecular structure **2013**, 434-452		
216	Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants. *Clinical Infectious Diseases*, **2013**, 57, 1368-9	11.6	9
215	Real-time influenza forecasts during the 2012-2013 season. *Nature Communications*, **2013**, 4, 2837	17.4	188
214	Pathogen diversity and hidden regimes of apparent competition. *American Naturalist*, **2013**, 181, 12-24	3.7	36

213	Population genomics of post-vaccine changes in pneumococcal epidemiology. *Nature Genetics*, **2013**, 45, 656-63	36.3	266
212	Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. *Nature Genetics*, **2013**, 45, 784-90	36.3	297
211	Broad conditions favor the evolution of phase-variable loci. *MBio*, **2013**, 4, e00430-12	7.8	22
210	Comparative genomics of recent Shiga toxin-producing Escherichia coli O104:H4: short-term evolution of an emerging pathogen. *MBio*, **2013**, 4, e00452-12	7.8	59
209	Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b. *Infection and Immunity*, **2013**, 81, 354-63	3.7	61
208	Within-host selection is limited by an effective population of Streptococcus pneumoniae during nasopharyngeal colonization. *Infection and Immunity*, **2013**, 81, 4534-43	3.7	21
207	Using pneumococcal carriage data to monitor postvaccination changes in invasive disease. *American Journal of Epidemiology*, **2013**, 178, 1488-95	3.8	50
206	Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. *Journal of Infectious Diseases*, **2013**, 208, 1266-73	7	37
205	Surface charge of Streptococcus pneumoniae predicts serotype distribution. *Infection and Immunity* , **2013**, 81, 4519-24	3.7	42
204	The El Nino-Southern Oscillation (ENSO)-pandemic influenza connection: coincident or causal?. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110 Suppl 1, 3689-91	11.5	31
203	Targeting imperfect vaccines against drug-resistance determinants: a strategy for countering the rise of drug resistance. *PLoS ONE*, **2013**, 8, e68940	3.7	28
202	Serotype replacement after pneumococcal vaccination □Authors' reply. *Lancet, The*, **2012**, 379, 1388-1389	40	8
201	Pneumococcal sequence type replacement among American Indian children: a comparison of pre- and routine-PCV7 eras. *Vaccine*, **2012**, 30, 2376-81	4.1	16
200	Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. *American Journal of Epidemiology*, **2012**, 175, 54-9	3.8	105
199	The prevalence and risk factors for pneumococcal colonization of the nasopharynx among children in Kilifi District, Kenya. *PLoS ONE*, **2012**, 7, e30787	3.7	75
198	Searching for sharp drops in the incidence of pandemic A/H1N1 influenza by single year of age. *PLoS ONE*, **2012**, 7, e42328	3.7	30
197	Factors related to increasing prevalence of resistance to ciprofloxacin and other antimicrobial drugs in Neisseria gonorrhoeae, United States. *Emerging Infectious Diseases*, **2012**, 18, 1290-7	10.2	37
196	Evolution, safety, and highly pathogenic influenza viruses. *Science*, **2012**, 336, 1529-31	33.3	26

195	Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae. *PLoS Pathogens*, **2012**, 8, e1002989	7.6	38
194	Cholera modeling: challenges to quantitative analysis and predicting the impact of interventions. *Epidemiology*, **2012**, 23, 523-30	3.1	48
193	Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes. *Science*, **2012**, 335, 1376-80	33.3	121
192	Modelling seasonal variations in the age and incidence of Kawasaki disease to explore possible infectious aetiologies. *Proceedings of the Royal Society B: Biological Sciences*, **2012**, 279, 2736-43	4.4	15
191	Vaccine allocation in a declining epidemic. *Journal of the Royal Society Interface*, **2012**, 9, 2798-803	4.1	9
190	Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities. *Journal of Infectious Diseases*, **2012**, 205, 280-8	7	81
189	Genomic epidemiology of the Escherichia coli O104:H4 outbreaks in Europe, 2011. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 3065-70	11.5	204
188	Rates of acquisition and clearance of pneumococcal serotypes in the nasopharynges of children in Kilifi District, Kenya. *Journal of Infectious Diseases*, **2012**, 206, 1020-9	7	61
187	Reply to Guy et al.: Support for a bottleneck in the 2011 Escherichia coli O104:H4 outbreak in Germany. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, E3629-30	11.5	2
186	Patient sharing and population genetic structure of methicillin-resistant Staphylococcus aureus. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 6763-8	11.5	21
185	Comment on "Seroevidence for H5N1 influenza infections in humans: meta-analysis". *Science*, **2012**, 336, 1506; author reply 1506	33.3	28
184	Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition model. *Epidemiology*, **2012**, 23, 510-9	3.1	65
183	Improving the estimation of influenza-related mortality over a seasonal baseline. *Epidemiology*, **2012**, 23, 829-38	3.1	110
182	Rethinking biosafety in research on potential pandemic pathogens. *MBio*, **2012**, 3,	7.8	23
181	Reply to Declining adherence as a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial *Aids*, **2012**, 26, 2262-2263	3.5	
180	Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. *Pediatric Infectious Disease Journal*, **2012**, 31, 249-54	3.4	63
179	Negative Control Exposures in Epidemiologic Studies. *Epidemiology*, **2012**, 23, 351-352	3.1	17
178	Clonal replacement among 19A Streptococcus pneumoniae in Massachusetts, prior to 13 valent conjugate vaccination. *Vaccine*, **2011**, 29, 8877-81	4.1	34

177	Serotype replacement in disease after pneumococcal vaccination. *Lancet, The*, **2011**, 378, 1962-73	40	661
176	Vaccine production, distribution, access, and uptake. *Lancet, The*, **2011**, 378, 428-38	40	64
175	Shortcomings of vitamin D-based model simulations of seasonal influenza. *PLoS ONE*, **2011**, 6, e20743	3.7	33
174	Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations. *Epidemiology*, **2011**, 22, 199-207	3.1	30
173	Carried pneumococci in Massachusetts children: the contribution of clonal expansion and serotype switching. *Pediatric Infectious Disease Journal*, **2011**, 30, 302-8	3.4	50
172	Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. *Nature Genetics*, **2011**, 43, 482-6	36.3	319
171	Changes in severity of 2009 pandemic A/H1N1 influenza in England: a Bayesian evidence synthesis. *BMJ, The*, **2011**, 343, d5408	5.9	66
170	Is methicillin-resistant Staphylococcus aureus replacing methicillin-susceptible S. aureus?. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 2199-214	5.1	50
169	Absolute humidity and pandemic versus epidemic influenza. *American Journal of Epidemiology*, **2011**, 173, 127-35	3.8	147
168	Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. *Clinical Infectious Diseases*, **2011**, 53, 277-9	11.6	92
167	Reply to Cochrane Neuraminidase Inhibitors Review Team. *Clinical Infectious Diseases*, **2011**, 53, 1303-1304	11.6	3
166	Predicting the epidemic sizes of influenza A/H1N1, A/H3N2, and B: a statistical method. *PLoS Medicine*, **2011**, 8, e1001051	11.6	113
165	S128 Highly invasive capsular serotypes of Streptococcus pneumoniae bind high levels of Factor H and are resistant to complement and phagocytosis. *Thorax*, **2011**, 66, A59-A59	7.3	
164	Estimating incidence curves of several infections using symptom surveillance data. *PLoS ONE*, **2011**, 6, e23380	3.7	6
163	Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1. *Biosecurity and Bioterrorism*, **2011**, 9, 89-115		78
162	Pre-dispensing of antivirals to high-risk individuals in an influenza pandemic. *Influenza and Other Respiratory Viruses*, **2010**, 4, 101-12	5.6	6
161	Student behavior during a school closure caused by pandemic influenza A/H1N1. *PLoS ONE*, **2010**, 5, e10425	3.7	34
160	Viral shedding and clinical illness in naturally acquired influenza virus infections. *Journal of Infectious Diseases*, **2010**, 201, 1509-16	7	229

159	What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae?. *Journal of the Royal Society Interface*, **2010**, 7, 905-19	4.1	64
158	Distribution of vaccine/antivirals and the 'least spread line' in a stratified population. *Journal of the Royal Society Interface*, **2010**, 7, 755-64	4.1	37
157	Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. *Clinical Infectious Diseases*, **2010**, 51, 692-9	11.6	262
156	Optimizing infectious disease interventions during an emerging epidemic. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 923-8	11.5	122
155	Absolute humidity and the seasonal onset of influenza in the continental United States. *PLoS Biology*, **2010**, 8, e1000316	9.7	420
154	Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling. *PLoS Medicine*, **2010**, 7, e1000275	11.6	69
153	Negative controls: a tool for detecting confounding and bias in observational studies. *Epidemiology*, **2010**, 21, 383-8	3.1	623
152	Mobile messaging as surveillance tool during pandemic (H1N1) 2009, Mexico. *Emerging Infectious Diseases*, **2010**, 16, 1488-9	10.2	9
151	Quantifying interhospital patient sharing as a mechanism for infectious disease spread. *Infection Control and Hospital Epidemiology*, **2010**, 31, 1160-9	2	56
150	The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model. *Vaccine*, **2010**, 28, 681-5	4.1	28
149	Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. *Vaccine*, **2010**, 28, 4842-6	4.1	53
148	Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. *Vaccine*, **2010**, 29, 283-8	4.1	93
147	Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009. *BMC Infectious Diseases*, **2010**, 10, 211	4	36
146	Quantifying child mortality reductions related to measles vaccination. *PLoS ONE*, **2010**, 5, e13842	3.7	18
145	Influenza seasonality: lifting the fog. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 3645-6	11.5	166
144	Impaired innate and adaptive immunity to Streptococcus pneumoniae and its effect on colonization in an infant mouse model. *Infection and Immunity*, **2009**, 77, 1613-22	3.7	54
143	Managing and reducing uncertainty in an emerging influenza pandemic. *New England Journal of Medicine*, **2009**, 361, 112-5	59.2	137
142	Estimates of the prevalence of pandemic (H1N1) 2009, United States, April-July 2009. *Emerging Infectious Diseases*, **2009**, 15, 2004-7	10.2	249

141	Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. *PLoS Medicine*, **2009**, 6, e1000085	11.6	63
140	The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. *PLoS Medicine*, **2009**, 6, e1000207	11.6	230
139	Pneumococcal capsular polysaccharide structure predicts serotype prevalence. *PLoS Pathogens*, **2009**, 5, e1000476	7.6	215
138	Continued impact of pneumococcal conjugate vaccine on carriage in young children. *Pediatrics*, **2009**, 124, e1-11	7.4	234
137	The pneumococcal pilus predicts the absence of Staphylococcus aureus co-colonization in pneumococcal carriers. *Clinical Infectious Diseases*, **2009**, 48, 760-3	11.6	40
136	Reconstructing influenza incidence by deconvolution of daily mortality time series. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 21825-9	11.5	52
135	Epidemiology and risk factors for Staphylococcus aureus colonization in children in the post-PCV7 era. *BMC Infectious Diseases*, **2009**, 9, 110	4	42
134	Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA. *Influenza and Other Respiratory Viruses*, **2009**, 3, 267-76	5.6	182
133	Exploring the relationship between incidence and the average age of infection during seasonal epidemics. *Journal of Theoretical Biology*, **2009**, 260, 175-85	2.3	10
132	Reproductive numbers, epidemic spread and control in a community of households. *Mathematical Biosciences*, **2009**, 221, 11-25	3.9	40
131	No coexistence for free: neutral null models for multistrain pathogens. *Epidemics*, **2009**, 1, 2-13	5.1	96
130	How to maintain surveillance for novel influenza A H1N1 when there are too many cases to count. *Lancet, The*, **2009**, 374, 1209-11	40	75
129	Time from illness onset to death, 1918 influenza and pneumococcal pneumonia. *Emerging Infectious Diseases*, **2009**, 15, 346-7	10.2	23
128	Understanding Australia's influenza pandemic policy on the strategic use of the antiviral drug stockpile. *Medical Journal of Australia*, **2009**, 191, 136-7	4	4
127	Predispensing of antivirals to high-risk individuals in an influenza pandemic. *PLOS Currents*, **2009**, 1, RRN1007		3
126	The severity of pandemic H1N1 influenza in the United States, April -- July 2009. *PLOS Currents*, **2009**, 1, RRN1042		24
125	Antiviral usage for H1N1 treatment: pros, cons and an argument for broader prescribing guidelines in the United States. *PLOS Currents*, **2009**, 1, RRN1122		4
124	H1N1 vaccination and adults with underlying health conditions in the US. *PLOS Currents*, **2009**, 1, RRN1132		3

123	Absolute humidity and the seasonal onset of influenza in the continental US. *PLOS Currents*, **2009**, 1, RRN1138		25
122	Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in Mexico. *PLoS ONE*, **2009**, 4, e6895	3.7	27
121	Generation interval contraction and epidemic data analysis. *Mathematical Biosciences*, **2008**, 213, 71-9	3.9	71
120	Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. *Infection and Immunity*, **2008**, 76, 2678-84	3.7	75
119	In vitro bactericidal activity of Streptococcus pneumoniae and bactericidal susceptibility of Staphylococcus aureus strains isolated from cocolonized versus noncocolonized children. *Journal of Clinical Microbiology*, **2008**, 46, 747-9	9.7	13
118	Too little of a good thing: a paradox of moderate infection control. *Epidemiology*, **2008**, 19, 588-9	3.1	3
117	Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. *Journal of Infectious Diseases*, **2008**, 197, 1511-8	7	102
116	Interleukin-17A mediates acquired immunity to pneumococcal colonization. *PLoS Pathogens*, **2008**, 4, e1000159	7.6	364
115	Does pneumococcal conjugate vaccine influence Staphylococcus aureus carriage in children?. *Clinical Infectious Diseases*, **2008**, 47, 289-91; author reply 291-2	11.6	14
114	Seasonality of antibiotic-resistant streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy?. *Journal of Infectious Diseases*, **2008**, 197, 1094-102	7	80
113	Patterns of antigenic diversity and the mechanisms that maintain them. *Journal of the Royal Society Interface*, **2007**, 4, 787-802	4.1	101
112	Little evidence for genetic susceptibility to influenza A (H5N1) from family clustering data. *Emerging Infectious Diseases*, **2007**, 13, 1074-6	10.2	30
111	The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. *Clinical Infectious Diseases*, **2007**, 44, 1115-22	11.6	44
110	How generation intervals shape the relationship between growth rates and reproductive numbers. *Proceedings of the Royal Society B: Biological Sciences*, **2007**, 274, 599-604	4.4	772
109	Serum antipneumococcal antibodies and pneumococcal colonization in adults with chronic obstructive pulmonary disease. *Journal of Infectious Diseases*, **2007**, 196, 928-35	7	25
108	Antiviral resistance and the control of pandemic influenza. *PLoS Medicine*, **2007**, 4, e15	11.6	163
107	Estimating variability in the transmission of severe acute respiratory syndrome to household contacts in Hong Kong, China. *American Journal of Epidemiology*, **2007**, 166, 355-63	3.8	43
106	Public health interventions and epidemic intensity during the 1918 influenza pandemic. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 7582-7	11.5	450

105	Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. *Journal of Infectious Diseases*, **2007**, 195, 347-52	7	118
104	Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. *Journal of Infectious Diseases*, **2007**, 196, 1221-7	7	54
103	Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. *Infection and Immunity*, **2007**, 75, 5460-4	3.7	79
102	Association of the pneumococcal pilus with certain capsular serotypes but not with increased virulence. *Journal of Clinical Microbiology*, **2007**, 45, 1684-9	9.7	71
101	SpxB is a suicide gene of Streptococcus pneumoniae and confers a selective advantage in an in vivo competitive colonization model. *Journal of Bacteriology*, **2007**, 189, 6532-9	3.5	79
100	Age- and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci. *Journal of Clinical Microbiology*, **2007**, 45, 948-52	9.7	98
99	How Do Antimicrobial Agents Lead to Resistance in Pathogens Causing Acute Respiratory Tract Infections?. *Infectious Diseases in Clinical Practice*, **2006**, 14, S6-S10	0.2	
98	Multiple outbreaks and flu containment plans. *Science*, **2006**, 312, 845	33.3	5
97	Interference between Streptococcus pneumoniae and Staphylococcus aureus: In vitro hydrogen peroxide-mediated killing by Streptococcus pneumoniae. *Journal of Bacteriology*, **2006**, 188, 4996-5001	3.5	144
96	Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. *American Journal of Epidemiology*, **2006**, 163, 160-70	3.8	44
95	Incremental increase in fitness cost with increased beta -lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. *Journal of Infectious Diseases*, **2006**, 193, 1296-303	7	55
94	The influence of hitchhiking and deleterious mutation upon asexual mutation rates. *Genetics*, **2006**, 173, 461-72	4	18
93	Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. *Infection and Immunity*, **2006**, 74, 2187-95	3.7	148
92	Upgrading antibiotic use within a class: tradeoff between resistance and treatment success. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 9655-60	11.5	35
91	Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 7042-7	11.5	97
90	Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. *PLoS Biology*, **2006**, 4, e90	9.7	128
89	Pandemic influenza: risk of multiple introductions and the need to prepare for them. *PLoS Medicine*, **2006**, 3, e135	11.6	30
88	Ethics of rationing the flu vaccine. *Science*, **2005**, 307, 41	33.3	4

87	Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. *Infection and Immunity*, **2005**, 73, 7043-6	3.7	62
86	Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?. *PLoS Medicine*, **2005**, 2, e15	11.6	99
85	Modeling community- and individual-level effects of child-care center attendance on pneumococcal carriage. *Clinical Infectious Diseases*, **2005**, 40, 1215-22	11.6	53
84	Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. *Journal of Infectious Diseases*, **2005**, 192, 367-76	7	129
83	CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 4848-53	11.5	294
82	Capsule homology does not increase the frequency of transformation of linked penicillin binding proteins PBP 1a and PBP 2x in Streptococcus pneumoniae. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 1591-2	5.9	2
81	Alert threshold algorithms and malaria epidemic detection. *Emerging Infectious Diseases*, **2004**, 10, 1220-6	10.2	36
80	Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 13285-90	11.5	267
79	Invited commentary: real-time tracking of control measures for emerging infections. *American Journal of Epidemiology*, **2004**, 160, 517-9; discussion 520	3.8	15
78	Age-specific immunoglobulin g (IgG) and IgA to pneumococcal protein antigens in a population in coastal kenya. *Infection and Immunity*, **2004**, 72, 3331-5	3.7	35
77	Single-step capsular transformation and acquisition of penicillin resistance in Streptococcus pneumoniae. *Journal of Bacteriology*, **2004**, 186, 3447-52	3.5	34
76	Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. *Clinical Infectious Diseases*, **2004**, 38, 1108-15	11.6	82
75	The analysis of hospital infection data using hidden Markov models. *Biostatistics*, **2004**, 5, 223-37	3.7	134
74	Transmissibility of 1918 pandemic influenza. *Nature*, **2004**, 432, 904-6	50.4	578
73	Weather-based prediction of Plasmodium falciparum malaria in epidemic-prone regions of Ethiopia II. Weather-based prediction systems perform comparably to early detection systems in identifying times for interventions. *Malaria Journal*, **2004**, 3, 44	3.6	62
72	Weather-based prediction of Plasmodium falciparum malaria in epidemic-prone regions of Ethiopia I. Patterns of lagged weather effects reflect biological mechanisms. *Malaria Journal*, **2004**, 3, 41	3.6	137
71	Effect of human leukocyte antigen heterozygosity on infectious disease outcome: the need for allele-specific measures. *BMC Medical Genetics*, **2003**, 4, 2	2.1	28
70	Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. *Nature Medicine*, **2003**, 9, 424-30	50.5	173

69	Transmission dynamics and control of severe acute respiratory syndrome. *Science*, **2003**, 300, 1966-70	33.3	1042
68	Multiple equilibria: tuberculosis transmission require unrealistic assumptions. *Theoretical Population Biology*, **2003**, 63, 169-70	1.2	22
67	Antibiotic resistance--the interplay between antibiotic use in animals and human beings. *Lancet Infectious Diseases, The*, **2003**, 3, 47-51	25.5	175
66	Construction of otherwise isogenic serotype 6B, 7F, 14, and 19F capsular variants of Streptococcus pneumoniae strain TIGR4. *Applied and Environmental Microbiology*, **2003**, 69, 7364-70	4.8	68
65	Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 1966-71	11.5	563
64	Antimicrobial use and antimicrobial resistance: a population perspective. *Emerging Infectious Diseases*, **2002**, 8, 347-54	10.2	319
63	Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. *Clinical Infectious Diseases*, **2002**, 34, 1558-63	11.6	144
62	Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States. *Sexually Transmitted Diseases*, **2002**, 29, 608-22	2.4	41
61	Potential benefits of a serodiagnostic test for herpes simplex virus type 1 (HSV-1) to prevent neonatal HSV-1 infection. *Sexually Transmitted Diseases*, **2002**, 29, 399-405	2.4	6
60	Antibiotics in agriculture: when is it time to close the barn door?. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 5752-4	11.5	102
59	Historical intensity of natural selection for resistance to tuberculosis. *Genetics*, **2002**, 161, 1599-607	4	33
58	Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. *Infection and Immunity*, **2001**, 69, 4870-3	3.7	147
57	Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. *Clinical Infectious Diseases*, **2001**, 32, 1044-54	11.6	100
56	Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposon. *Infection and Immunity*, **2001**, 69, 3350-8	3.7	217
55	Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes. *American Journal of Epidemiology*, **2001**, 154, 85-92	3.8	48
54	The rise and fall of antimicrobial resistance. *Trends in Microbiology*, **2001**, 9, 438-44	12.4	142
53	Microbiology. Bacterial population genetics and disease. *Science*, **2001**, 292, 59-60	33.3	6
52	Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 2485-91	5.9	104

51	The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 1938-43	11.5	296
50	Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 2824-33	5.9	16
49	Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. *Vaccine*, **2000**, 18, 2895-901	4.1	98
48	Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. *Emerging Infectious Diseases*, **1999**, 5, 336-45	10.2	214
47	Population biology, evolution, and infectious disease: convergence and synthesis. *Science*, **1999**, 283, 806-9	33.3	191
46	The population genetics of antibiotic resistance. II: Analytic theory for sustained populations of bacteria in a community of hosts. *Theoretical Population Biology*, **1998**, 53, 152-65	1.2	36
45	Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. *International Journal of Tuberculosis and Lung Disease*, **1998**, 2, 187-99	2.1	78
44	The population genetics of antibiotic resistance. *Clinical Infectious Diseases*, **1997**, 24 Suppl 1, S9-16	11.6	211
43	Evaluating treatment protocols to prevent antibiotic resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 12106-11	11.5	368
42	TRANSMISSION RATES AND HIV VIRULENCE: COMMENTS TO MASSAD. *Evolution; International Journal of Organic Evolution*, **1997**, 51, 319-320	3.8	7
41	Transmission Rates and HIV Virulence: Comments to Massad. *Evolution; International Journal of Organic Evolution*, **1997**, 51, 319	3.8	1
40	Virulence and transmissibility of pathogens: what is the relationship?. *Trends in Microbiology*, **1997**, 5, 31-7	12.4	253
39	Vaccination against colonizing bacteria with multiple serotypes. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 6571-6	11.5	190
38	The population dynamics of antimicrobial chemotherapy. *Antimicrobial Agents and Chemotherapy*, **1997**, 41, 363-73	5.9	181
37	The within-host population dynamics of antibacterial chemotherapy: conditions for the evolution of resistance. *Novartis Foundation Symposium*, **1997**, 207, 112-27; discussion 127-30		4
36	THE EVOLUTION OF VIRULENCE IN PATHOGENS WITH VERTICAL AND HORIZONTAL TRANSMISSION. *Evolution; International Journal of Organic Evolution*, **1996**, 50, 1729-1741	3.8	173
35	Host Population Structure and the Evolution of Virulence: A "Law of Diminishing Returns". *Evolution; International Journal of Organic Evolution*, **1995**, 49, 743	3.8	69
34	Virulence and transmission modes of two microsporidia in Daphnia magna. *Parasitology*, **1995**, 111, 133-142	2.7	58

33	HOST POPULATION STRUCTURE AND THE EVOLUTION OF VIRULENCE: A "LAW OF DIMINISHING RETURNS". *Evolution; International Journal of Organic Evolution*, **1995**, 49, 743-748	3.8	13
32	The evolution of virulence in sexually transmitted HIV/AIDS. *Journal of Theoretical Biology*, **1995**, 174, 427-40	2.3	82
31	Infectious disease dynamics and restrictions on social gathering size		1
30	Equitable COVID-19 vaccine prioritization: front-line workers or 65-74 year olds?		2
29	Targeted surveillance strategies for efficient detection of novel antibiotic resistance variants		1
28	Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China		48
27	Impact of antimicrobial treatment for acute otitis media on carriage dynamics of penicillin-susceptible and penicillin□on-susceptible Streptococcus pneumoniae: secondary analysis of a randomized, double-blind, placebo-controlled trial		1
26	Population genomics of pneumococcal carriage in Massachusetts children following PCV-13 introduction		2
25	Estimating the proportion of bystander selection for antibiotic resistance in the US		2
24	Levels of outpatient prescribing for four major antibiotic classes and rates of septicemia hospitalization in adults in different US states		4
23	Resistance diagnostics as a public health tool to combat antibiotic resistance: A model-based evaluation		1
22	The distribution of antibiotic use and its association with antibiotic resistance		1
21	Programmatic goals and spatial epidemiology influence the merit of targeted versus of population-wide interventions for yaws eradication		2
20	Nowcasting by Bayesian Smoothing: A flexible, generalizable model for real-time epidemic tracking		3
19	Fractional Dosing of Yellow Fever Vaccine to Extend Supply: A Modeling Study		1
18	Host population structure and treatment frequency maintain balancing selection on drug resistance		1
17	The role of absolute humidity on transmission rates of the COVID-19 outbreak		101
16	Projecting the transmission dynamics of SARS-CoV-2 through the post-pandemic period		96

15	Social distancing strategies for curbing the COVID-19 epidemic		109
14	Leveraging pathogen sequence and contact tracing data to enhance vaccine trials in emerging epidemics		2
13	Quantifying biases in test-negative studies of vaccine effectiveness		2
12	Use of an individual-based model of pneumococcal carriage for planning a randomized trial of a vaccine		1
11	Trends in outpatient antibiotic prescribing practice among US older adults, 2011-2015: an observational study		1
10	Predicting evolution using frequency-dependent selection in bacterial populations		5
9	Hospitalizations associated with respiratory syncytial virus (RSV) and influenza in children, including children having a diagnosis of asthma		1
8	Competing effects of indirect protection and clustering on the power of cluster-randomized controlled vaccine trials		1
7	SARS-CoV-2 infection and risk of clinical sequelae during the post-acute phase: a retrospective cohort study		5
6	Estimating vaccine efficacy against transmission via effect on viral load		3
5	Identifying and alleviating bias due to differential depletion of susceptible people in post-marketing evaluations of COVID-19 vaccines		3
4	Decreased Infectivity Following BNT162b2 Vaccination. *SSRN Electronic Journal*,	1	9
3	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape		2
2	Modeling the impact of racial and ethnic disparities on COVID-19 epidemic dynamics		1
1	Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against SARS-CoV-2 Variant Beta (B.1.351) Among Persons Identified Through Contact Tracing in Israel. *SSRN Electronic Journal*,	1	2